IntegraGen announced today its unaudited business figures for the year 2019.

  • 2019 revenue amounted to 8.3 M € versus 6.9 M € in 2018, an increase of 20% over 12 months.
  • This performance highlights an acceleration from the high growth level of 15% reported for the first half of 2019.
  • Strong increase in sequencing services, driven by activities related to the SeqOIA sequencing platform and by activities with the Institut Pasteur
  • Sales growth for Mercury®, Sirius® and Galileo® sequencing data interpretation software
  • Generation of positive operational cash flow in the second half enabling a cash balance of €2.8 million compared with €2.6 million at June 30, 2019

Click here to view press release.

Attachments

  • Original document
  • Permalink

Disclaimer

IntegraGen SA published this content on 10 January 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 January 2020 07:37:09 UTC